Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-11-07 Sale |
2023-11-08 4:22 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
382 | $12.65 | $4,832 | 124,511 (Direct) |
View |
| 2023-09-01 Sale |
2023-09-05 4:24 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
883 | $21.82 | $19,265 | 99,650 (Direct) |
View |
| 2023-09-01 Sale |
2023-09-05 4:24 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
294 | $21.82 | $6,414 | 209,825 (Direct) |
View |
| 2023-09-01 Sale |
2023-09-05 4:23 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
273 | $21.82 | $5,956 | 124,893 (Direct) |
View |
| 2023-08-02 Sale |
2023-08-04 4:02 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,144 | $30.25 | $34,607 | 100,533 (Direct) |
View |
| 2023-03-03 Sale |
2023-03-07 4:52 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
13,609 | $75.55 | $1,028,165 | 54,284 (Direct) |
View |
| 2023-03-03 Sale |
2023-03-07 4:52 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
21,421 | $76.16 | $1,631,411 | 124,799 (Direct) |
View |
| 2023-03-03 Sale |
2023-03-07 4:51 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
25,635 | $76.16 | $1,952,346 | 209,753 (Direct) |
View |
| 2023-03-03 Sale |
2023-03-07 4:51 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
5,505 | $76.16 | $419,257 | 101,310 (Direct) |
View |
| 2023-03-03 Sale |
2023-03-07 4:50 pm |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
593 | $76.16 | $45,163 | 66,090 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-06 4:42 pm |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
281 | $75.28 | $21,153 | 66,683 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-06 4:41 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
937 | $75.28 | $70,535 | 146,220 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-06 4:40 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
1,213 | $75.28 | $91,312 | 235,388 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-06 4:40 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,055 | $75.28 | $79,418 | 106,815 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-06 4:37 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
2,903 | $76.95 | $223,393 | 67,893 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-03 4:13 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
4,107 | $75.38 | $309,578 | 58,988 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
Ownership |
2023-12-20 4:23 pm |
N/A N/A |
NovoCure Ltd | NVCR | Giladi Moshe Chief Science Officer |
0 | $0 | 61,032 (Direct) |
View |
| 2023-10-31 Option Award |
2023-11-03 4:08 pm |
N/A N/A |
NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer |
37,593 | $0 | 95,197 (Direct) |
View |
| 2023-10-31 Option Award |
2023-11-03 4:08 pm |
2024-10-31 2033-10-30 |
NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer |
57,604 | $13.3 | 95,197 (Direct) |
View |
| 2023-10-31 Exercise |
2023-11-02 4:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
2,480 | $11.44 | 117,793 (Direct) |
View |
| 2023-10-31 Exercise |
2023-11-02 4:20 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
17,968 | $0 | 117,793 (Direct) |
View |
| 2023-10-31 Exercise |
2023-11-02 4:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
7,752 | $7.15 | 117,793 (Direct) |
View |
| 2023-10-31 Exercise |
2023-11-02 4:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
7,736 | $11.46 | 117,793 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer |
305 | $35.28 | 89,349 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
366 | $35.28 | 210,119 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
367 | $35.28 | 125,166 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
357 | $35.28 | 66,447 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
288 | $35.28 | 35,195 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
367 | $35.28 | 101,677 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:12 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
367 | $35.28 | 13,989 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:05 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | VERNON W ANTHONY Director |
10,130 | $0 | 172,074 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:05 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
10,130 | $0 | 10,205 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:04 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | Hung David Director |
12,554 | $0 | 12,554 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:04 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | Madden Martin J. Director |
12,554 | $0 | 12,554 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:04 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
10,130 | $0 | 85,416 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:04 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | HILLEMAN JERYL L Director |
12,554 | $0 | 12,554 (Direct) |
View |
| 2023-05-09 Option Award(A) |
2023-05-17 4:58 pm |
N/A 2033-05-08 |
NovoCure Ltd | NVCR | Stafford Kristin Director |
15,873 | $0 | 15,873 (Direct) |
View |
| 2023-05-09 Option Award |
2023-05-11 4:34 pm |
N/A 2033-05-08 |
NovoCure Ltd | NVCR | Stafford Kristin Director |
15,873 | $0 | 15,873 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-06 4:43 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer |
32,766 | $0 | 89,044 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-06 4:41 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
47,182 | $0 | 146,220 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-06 4:40 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
51,986 | $0 | 235,388 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-06 4:40 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
11,808 | $0 | 106,815 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-06 4:37 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
11,808 | $0 | 67,893 (Direct) |
View |
Ownership |
2023-03-03 4:09 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Ocean Allyson J Director |
0 | $0 | 13,989 (Direct) |
View |